Compare CABO & CUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CABO | CUVL |
|---|---|---|
| Founded | 1980 | 1999 |
| Country | United States | Australia |
| Employees | N/A | 16 |
| Industry | Cable & Other Pay Television Services | Miscellaneous |
| Sector | Telecommunications | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 425.5M | 374.2M |
| IPO Year | 2015 | N/A |
| Metric | CABO | CUVL |
|---|---|---|
| Price | $5.57 | $5.00 |
| Analyst Decision | Hold | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $44.25 | N/A |
| AVG Volume (30 Days) | ★ 803.4K | 4.9K |
| Earning Date | 11-05-2026 | 08-27-2026 |
| Dividend Yield | N/A | ★ 0.56% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,501,423,000.00 | N/A |
| Revenue This Year | N/A | $0.89 |
| Revenue Next Year | $4.86 | $6.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.37 | $4.91 |
| 52 Week High | $167.36 | $8.20 |
| Indicator | CABO | CUVL |
|---|---|---|
| Relative Strength Index (RSI) | 26.87 | 30.44 |
| Support Level | N/A | $4.91 |
| Resistance Level | $16.31 | $6.04 |
| Average True Range (ATR) | 2.13 | 0.15 |
| MACD | -0.11 | -0.02 |
| Stochastic Oscillator | 1.92 | 10.09 |
Cable One Inc is a telecommunications company that generates revenue from providing broadband, voice, and video services to both residential and business customers. The company derives majority of its revenue from data and video services, which are subscription-based and billed monthly. The company also offers Sparklight TV, an Internet Protocol Television (IPTV) service that enables customers using the Sparklight TV app to stream video channels from the cloud. Additionally, the company earns advertising revenue by selling airtime on its video channels, and it provides voice services over Internet protocols.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.